{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:29:41Z","timestamp":1790270981091,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.bulcan.2014.12.012","type":"journal-article","created":{"date-parts":[[2015,1,29]],"date-time":"2015-01-29T18:18:05Z","timestamp":1422555485000},"page":"190-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["N\u00e9phrotoxicit\u00e9 du pemetrexed"],"prefix":"10.1016","volume":"102","author":[{"given":"Hassan","family":"Izzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2014.12.012_bib0005","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1200\/JCO.2003.06.122","article-title":"Phase II study of pemetrexed with and without folic acid and vitamin B12\u00a0as front-line therapy in malignant pleural mesothelioma","volume":"21","author":"Scagliotti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0010","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1200\/JCO.1999.17.4.1194","article-title":"Multitargeted antifolate, LY231514, as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study\u00a0\u2013\u00a0National Cancer Institute of Canada Clinical Trials Group","volume":"17","author":"Rusthoven","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0015","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L","article-title":"Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study","volume":"88","author":"John","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1008305205159","article-title":"Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer","volume":"11","author":"Miller","year":"2000","journal-title":"Ann Oncol"},{"issue":"suppl. 6","key":"10.1016\/j.bulcan.2014.12.012_bib0025","first-page":"99","article-title":"Overview of phase II trials of MTA in solid tumors","volume":"26","author":"O\u2019Dwyer","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1634\/theoncologist.6-4-363","article-title":"Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors","volume":"6","author":"Hanauske","year":"2001","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CBC.2001.n.010","article-title":"Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis","volume":"2","author":"Spielmann","year":"2001","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0065-2571(97)00017-4","article-title":"Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA)","volume":"38","author":"Shih","year":"1998","journal-title":"Adv Enzyme Regul"},{"issue":"suppl 3","key":"10.1016\/j.bulcan.2014.12.012_bib0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/bjc.1998.751","article-title":"Preclinical cellular pharmacology of LY231514 (MTA): A comparison with methotrexate, LY309887\u00a0and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells","volume":"78","author":"Chen","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0050","doi-asserted-by":"crossref","first-page":"8089","DOI":"10.1016\/S0040-4020(01)80479-8","article-title":"Synthesis of pyrazolo[3,4-d] pyrimidineanaloguesofthepotentagentN-{4-[2-(2-amino- 4(3H)-oxo-7H-pyrrolo[2,3-dpyrimidin-5-yl]ethyl]benzoyl}-Lglutamic acid (LY231514)","volume":"48","author":"Taylor","year":"1992","journal-title":"Tetrahedron"},{"issue":"suppl 6","key":"10.1016\/j.bulcan.2014.12.012_bib0055","first-page":"42","article-title":"Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis","volume":"2","author":"Mendelsohn","year":"1999","journal-title":"Semin Oncol"},{"issue":"suppl 6","key":"10.1016\/j.bulcan.2014.12.012_bib0060","first-page":"82","article-title":"Overview of phase I trials of multitargeted antifolate (MTA, LY231514)","volume":"2","author":"Rinaldi","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0065","first-page":"235a","article-title":"Comparative human pharmacokinetics of MTA in three phase I studies","volume":"17","author":"Sharma","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0070","unstructured":"U.S. Food and Drug Administration: Center for drug evaluation and research: Alimta (Pemetrexed for injection): Label and patient package insert, 5\/04\u00a0created. http:\/\/www.fda.gov\/cder\/drug\/infopage\/alimta\/default.htm."},{"key":"10.1016\/j.bulcan.2014.12.012_bib0075","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/1078-0432.CCR-05-1834","article-title":"Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or ibuprofen in patients with advanced cancer","volume":"12","author":"Sweeney","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0080","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603321","article-title":"A phase I study of Pemetrexed (LY231514) supplemented with folate and vitamin B12\u00a0in Japanese patients with solid tumours","volume":"95","author":"Nakagawa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s002800050992","article-title":"A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21\u00a0days, utilizing the modified continual reassessment method for dose escalation","volume":"44","author":"Rinaldi","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","article-title":"Phase 1\u00a0and pharmacokinetic study of pemetrexed administered every 3\u00a0weeks to advanced cancer patients with normal and impaired function","volume":"24","author":"Mita","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0095","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1592\/phco.26.5.641","article-title":"Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy","volume":"26","author":"Villela","year":"2006","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.57.2.110","article-title":"Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients","volume":"57","author":"Bressolle","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0105","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/bjc.1998.652","article-title":"Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694)","volume":"78","author":"Judson","year":"1998","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.bulcan.2014.12.012_bib0110","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.3816\/CLC.2004.s.003","article-title":"Pharmacology and mechanism of action of pemetrexed","volume":"5","author":"Adjei","year":"2004","journal-title":"Clin Lung Cancer"},{"issue":"suppl 3","key":"10.1016\/j.bulcan.2014.12.012_bib0115","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/bjc.1998.752","article-title":"Clinical studies with MTA","volume":"78","author":"Calvert","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0120","first-page":"3","article-title":"An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents","volume":"26","author":"Calvert","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0125","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1096\/fasebj.7.14.7901104","article-title":"Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency","volume":"7","author":"Allen","year":"1993","journal-title":"FASEB J"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0130","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/archinte.159.12.1289","article-title":"Laboratory diagnosis of vitamin B12\u00a0and folate deficiency: a guide for the primary care physician","volume":"159","author":"Snow","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0135","first-page":"321","article-title":"The assessment of the vitamin B6\u00a0status among Egyptian school children by measuring the urinary cystathionine excretion","volume":"54","author":"Arafa","year":"1984","journal-title":"Int J Vitam Nutr Res"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0140","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1586\/14737140.3.2.145","article-title":"Pemetrexed (Alimta): a novel multitargeted antifolate agent","volume":"3","author":"Adjei","year":"2003","journal-title":"Exp Rev Anticancer Ther"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0145","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-06-2393","article-title":"and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer","volume":"13","author":"Takimoto","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01243894-200601000-00007","article-title":"Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma","volume":"1","author":"van den Bogaert","year":"2006","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0155","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-06-2377","article-title":"A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer","volume":"13","author":"Llombart-Cussac","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0160","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1634\/theoncologist.9-5-482","article-title":"FDA drug approval summaries: pemetrexed (Alimta)","volume":"9","author":"Hazarika","year":"2004","journal-title":"Oncologist"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0165","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1200\/JCO.2006.09.9887","article-title":"trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma","volume":"26","author":"Jassem","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0170","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3\u00a0study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bulcan.2014.12.012_bib0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.lungcan.2014.07.005","article-title":"Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: a cross-trial comparison of two phase III trials","volume":"85","author":"Scagliotti","year":"2014","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.bulcan.2014.12.012_bib0180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.cllc.2014.06.007","volume":"15","author":"Pujol","year":"2014","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.bulcan.2014.12.012_bib0185","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1097\/JTO.0000000000000207","article-title":"Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study","volume":"9","author":"Gridelli","year":"2014","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0190","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00280-005-0036-1","article-title":"Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients","volume":"57","author":"Latz","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0195","series-title":"Center for Drug Evaluation and Research: Alimta","author":"U.S. Food and Drug Administration","year":"2004"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0200","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1200\/JCO.2003.99.092","article-title":"Thymidine rescue: an antidote for pemetrexed related toxicity in the setting of acute renal failure","volume":"21","author":"Castro","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0205","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1385\/MO:23:3:419","article-title":"Pemetrexed-induced acute renal failure, nephrogenic diabetes insipidus, and renal tubular acidosis in a patient with non-small-cell lung cancer","volume":"23","author":"Vootukuru","year":"2006","journal-title":"Med Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0210","first-page":"610","article-title":"Acute renal failure associated with pemetrexed (Alimta)","volume":"29","author":"Porta","year":"2009","journal-title":"Nefrologia"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0215","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000208377","article-title":"Acute tubular necrosis and interstitial nephritis during pemetrexed therapy","volume":"2","author":"Michels","year":"2009","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0220","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3109\/0886022X.2010.501930","article-title":"Interstitial nephritis and nephrogenic diabetes insipidus in a patient treated with pemetrexed","volume":"32","author":"Stavroulopoulos","year":"2010","journal-title":"Ren Fail"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0225","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1053\/j.ajkd.2011.04.030","article-title":"Kidney tubular toxicity of maintenance pemetrexed therapy","volume":"58","author":"Glezerman","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.bulcan.2014.12.012_bib0230","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5414\/CN107921","article-title":"Pemetrexed-induced acute kidney injury leading to chronic kidney disease","volume":"82","author":"Chauvet","year":"2014","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0235","doi-asserted-by":"crossref","DOI":"10.1007\/s40620-014-0117-5","article-title":"Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage","author":"Rombola","year":"2014","journal-title":"J Nephrol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0240","doi-asserted-by":"crossref","first-page":"e97888","DOI":"10.1371\/journal.pone.0097888","article-title":"Pemetrexed induces S-phase arrest and apoptosis via a deregulated activation of Akt signaling pathway","volume":"9","author":"Chen","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0245","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1124\/jpet.103.061812","article-title":"Quantitative evaluation of the drug-drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier","volume":"309","author":"Nozaki","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0250","doi-asserted-by":"crossref","first-page":"F22","DOI":"10.1152\/ajprenal.00385.2005","article-title":"The kidney in vitamin B12\u00a0and folate homeostasis: characterization of receptors for tubular uptake of vitamins and carrier proteins","volume":"291","author":"Birn","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0255","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.drup.2006.09.001","article-title":"The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis","volume":"9","author":"Assaraf","year":"2006","journal-title":"Drug Resist Update"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/BF00258131","article-title":"The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)","volume":"14","author":"Alison","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0265","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1124\/mol.104.004978","article-title":"Characterization of binding of folates and antifolates to brush-border membrane vesicles isolated from human kidney","volume":"67","author":"Damaraju","year":"2005","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0270","first-page":"F122","article-title":"Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney","volume":"276","author":"Hosoyamada","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0275","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1124\/mol.59.5.1277","article-title":"Identification and characterization of human organic anion transporter 3\u00a0expressing predominantly in the kidney","volume":"59","author":"Cha","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0280","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0014-5793(98)01328-3","article-title":"Functional characterization of the rat multispecific organic anion transporter OAT1\u00a0mediating basolateral uptake of anionic drugs in the kidney","volume":"438","author":"Uwai","year":"1998","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0285","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2133\/dmpk.DMPK-13-RG-042","article-title":"Characteristics of pemetrexed transport by renal basolateral organic anion transporter hOAT3","volume":"29","author":"Kurata","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0290","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/S0140-6736(86)91706-X","article-title":"Acute renal failure due to concomitant action of methotrexate and indomethacin","volume":"1","author":"Maiche","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0295","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2133\/dmpk.19.369","article-title":"Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1\u00a0and hOAT3","volume":"19","author":"Uwai","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0300","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.bcp.2005.06.024","article-title":"Human organic anion transporter hOAT3\u00a0is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1","volume":"70","author":"Ueo","year":"2005","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0305","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejphar.2003.10.017","article-title":"Evidence for a role of human organic anion transporters in the muscular side effects of HMG-CoA reductase inhibitors","volume":"483","author":"Takeda","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0310","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/mol.57.4.760","article-title":"Interactions of the human multidrug resistance proteins MRP1\u00a0and MRP2\u00a0with organic anions","volume":"57","author":"Bakos","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0315","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1042\/bj20030150","article-title":"A functional study on polymorphism of the ATP-binding cassette transporter ABCG2: critical role of arginine-482\u00a0in methotrexate transport","volume":"373","author":"Mitomo","year":"2003","journal-title":"Biochem J"},{"key":"10.1016\/j.bulcan.2014.12.012_bib0320","first-page":"5538","article-title":"Wild-type breast cancer resistance protein (BCRP\/ABCG2) is a methotrexate polyglutamate transporter","volume":"63","author":"Volk","year":"2003","journal-title":"Cancer Res"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455114000204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455114000204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T05:32:04Z","timestamp":1566279124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455114000204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0007455114000204"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2014.12.012","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"N\u00e9phrotoxicit\u00e9 du pemetrexed","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2014.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}